Today, Kringle Pharma, Inc., a portfolio company of the Keio Innovation Initiative No. 1 Investment Limited Partnership managed by the Keio Innovation Initiative (KII), was listed on the Mothers market of the Tokyo Stock Exchange.

Kringle Pharma is collaborating with Keio University, Osaka University, and Tohoku University to develop hepatocyte growth factor (HGF), discovered at Osaka University, as a treatment for spinal cord injury, ALS, and other rare diseases for which there is no effective therapy.

Go to Kringle Pharma’s website
https://www.kringle-pharma.com/